Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612744 | 0.97 | GHSR (0.80) | GHSRMLNR | |
| SCHEMBL13626804 | 0.94 | GHSR (0.66) | GHSRMLNR | |
| SCHEMBL13612795 | 0.94 | GHSR (0.66) | GHSRMLNR | |
| SCHEMBL13612791 | 0.94 | GHSR (0.66) | GHSRMLNR | |
| SCHEMBL13612785 | 0.93 | GHSR (0.75) | GHSRMLNR | |
| SCHEMBL13612754 | 0.91 | GHSR (0.70) | GHSRMLNR | |
| SCHEMBL13612750 | 0.90 | GHSR (0.70) | GHSRMLNR | |
| SCHEMBL13612766 | 0.90 | GHSR (0.80) | GHSRMLNR | |
| SCHEMBL13612768 | 0.89 | GHSR (0.77) | GHSRMLNR | |
| SCHEMBL13612796 | 0.88 | GHSR (0.75) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | GHSR, GIPR, GHRHR | GHSR 1/4885MLNR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.